<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605592</url>
  </required_header>
  <id_info>
    <org_study_id>12839</org_study_id>
    <nct_id>NCT00605592</nct_id>
  </id_info>
  <brief_title>UVA Islet Cell Transplantation in Patients With Type I Diabetes</brief_title>
  <official_title>UVA Islet Cell Transplantation in Patients With Type I Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will provide islet cell transplantation to two separate populations in need of&#xD;
      a pancreas transplant:&#xD;
&#xD;
      Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems&#xD;
&#xD;
      Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney&#xD;
      Transplant&#xD;
&#xD;
      The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and&#xD;
      may benefit from transplantation over continuing insulin therapy, even though chronic&#xD;
      immunosuppression is required. We believe that in these patients, the islet transplant&#xD;
      procedure promises enough potential benefit to justify subjecting patients who have not&#xD;
      previously had a transplant to the risk of immunosuppression.&#xD;
&#xD;
      In patients who are already subject to the dangers of chronic immunosuppression for other&#xD;
      reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure&#xD;
      itself is the principal additional risk and this risk should be minimal. In these patients&#xD;
      (our Group II), the potential benefit from improved glycemic control is that it promises to&#xD;
      slow or even reverse diabetic complications, such as vascular problems leading to kidney&#xD;
      damage. It is this rationale that has made pancreas transplantation a widely accepted option&#xD;
      in patients with renal failure, despite the risks associated with whole pancreas&#xD;
      transplantation. Islet cell transplantation aims to provide a potentially lower risk&#xD;
      procedure that has similar relief from diabetic complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A decrease in the average daily insulin requirement post-islet cell transplantation.</measure>
    <time_frame>Post-transplant</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic Islets of Langerhans Cell Transplant</intervention_name>
    <description>Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Islet Cell Transplant</other_name>
    <other_name>Pancreatic Islet Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type I Diabetes Mellitus for at least 5 years&#xD;
&#xD;
          -  Unstable control of diabetes despite intensive care by an endocrinologist, including&#xD;
             episodes of dangerously low blood sugars&#xD;
&#xD;
          -  Group I must have healthy kidneys&#xD;
&#xD;
          -  Group II (islet after kidney) must have a stable kidney allograft for at least 6&#xD;
             months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable diabetic eye disease&#xD;
&#xD;
          -  Poor kidney function&#xD;
&#xD;
          -  Type II Diabetes as determined by blood tests&#xD;
&#xD;
          -  Any history of cancer, except certain skin cancers&#xD;
&#xD;
          -  Pregnant or unwilling to use adequate birth control&#xD;
&#xD;
          -  Very high hemoglobin A1c levels&#xD;
&#xD;
          -  Poor control of blood pressure, despite use of medications&#xD;
&#xD;
          -  Very high insulin requirements&#xD;
&#xD;
          -  History of exposure to HIV&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Brayman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <last_update_submitted>February 16, 2009</last_update_submitted>
  <last_update_submitted_qc>February 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Brayman/MD, PhD</name_title>
    <organization>University of Virginia</organization>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Kidney Transplant</keyword>
  <keyword>Hypoglycemic Unawareness</keyword>
  <keyword>Islet Transplant</keyword>
  <keyword>Pancreatic Islet Cell Transplantation</keyword>
  <keyword>University of Virginia</keyword>
  <keyword>Islet Transplantation</keyword>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

